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Background. To estimate the exposure to medicines with unknown fetal risk during pregnancy and to analyze the maternal
characteristics associated with it. Methods. A questionnaire was administered to 4,189 mothers of children belonging to the 2004
Pelotas (Brazil) birth cohort study about use of any medicine during gestation. We evaluated the associations between use of
medicines with unknown fetal risk and the independent variables through logistic regression models. Unknown fetal risk was
defined as medicines in which studies in animals have revealed adverse effects on the fetus, and no controlled studies in women,
or studies in women and animals, are available. Results. Out of the 4,189 women, 52.5% used at least one medicine from unknown
fetal risk. Use of these medicines was associated with white skin color, high schooling, high income, six or more antenatal care
consultations, hospital admission during pregnancy, and morbidity during gestation. Conclusion. The use of unknown fetal risk
medicines is high, suggesting that their use must be addressed with caution with the aim of restricting their use to cases in which
the benefits are greater than the potential risks.
1. Background
Studies have demonstrated high prevalence of medicine use
during pregnancy. The exposure to at least one medicine dur-
ing pregnancy is most often exceeding 70% [1–10]. A recent
systematic review, which evaluated medicine use prescribed
during pregnancy in developed countries, showed that 27 to
93% of the pregnant women received at least one prescrip-
tion of medicine, excluding vitamins and minerals [11].
In many situations the use may be unnecessary and even
dangerous for the fetus, although one should consider that in
most cases the use of medicines to treat chronic conditions
and problems associated with pregnancy can be vital to the
health and well-being of the woman and the offspring [12,
13].
Prescription of medicines during pregnancy is challeng-
ing for doctors because they need to balance the benefits
of the treatment against possible damages to the fetus [14].
Most studies evaluating the risk that medicines pose to the
fetus used the US Food and Drug Administration (FDA)
classification [15]. Such studies have shown that exposure
to category A medicines (considered safe during pregnancy)
occurred in 49% to 100% of the participating women [5,
7, 16, 17]. Medicines with evidence of fetal risk (category
D and X) were used by less than 12% of pregnant women
[1, 5, 7, 17–20], with the exception of a study conducted in
France, in which the percentage of exposure to category D
drugs was 59% [16]. Many studies focused on the factors
associated with the use of products from categories D or X
[18, 19, 21, 22].
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The most challenging category of medicines in this case,
however, is the one in which the risk to the fetus is unknown,
classified by the FDA in Category C. This group represents
an important fraction when considering the quantity of
prescribed drugs and the number of exposed women. Studies
indicate that the use of unknown fetal risk medicines during
pregnancy ranges from 19% to 40% [1, 5, 6, 23]. The present
study aimed to verify the prevalence of use of medicines
with unknown fetal risk during pregnancy and to analyze
maternal characteristics associated with this outcome.
2. Methods
In 2004, the third birth cohort in the city of Pelotas, southern
Brazil was initiated. In this study, all mothers of babies
born in the city’s five maternities (99% of all births) were
interviewed within the first 24 hours that succeeded child-
birth. A standardized precoded questionnaire was applied,
including questions about the use of any medicine during
pregnancy and the initiation month and termination of
this usage. The question about medicine use was: “Please,
let us know the name of all medicines that you have
used during pregnancy. Please remember to consider those
used for nausea, heartburn, anemia, treatment of urinary
tract infection, vaginal infection, high blood pressure, or
diabetes.” Further details on the methodology of the cohort
can be found elsewhere [24].
Medicines with unknown fetal risk were classified as
those in which studies in animals have revealed adverse
effects on the fetus (teratogenic or embryocidal or other),
and there are no controlled studies in women or studies in
women and animals are not available.
We decided to use criteria adopted by the FDA [15] for
the category C, in order to enable possible comparisons since
this is the most frequent classification found in different
studies. Medicines showing evidence about risk, leading to
damage or safety of the fetus, were classified as medicines
with known fetal risk.
Firstly, the drug monograph was queried in the DRUGD-
EX System [25], followed by consultation of the Guide to
Fetal and Neonatal Risk by Briggs et al. [26]. When the
information was not located in any of the two sources, a
search in PubMed was performed by intersecting the drug
name with keywords related to pregnancy and teratogenic-
ity/adverse effects. Medicines without any information about
the teratogenic risk were classified as unknown fetal risk [26],
in accordance with previous studies [5, 23]. Medicines were
also classified as unknown fetal risk when information was
available on the risk of the therapeutic group, but not the
medicine itself (e.g., benzodiazepines versus bromazepam).
When information was available on the risk of the active
substance, but not for the salts, the classification of the
main element was adopted (e.g., when there was information
for iron, but not for the iron polymaltose). In the case of
medicines for which the risk category changes depending on
the dose (e.g., ferrous sulphate) the classification was based
on the most common prescribed dose. When drugs were
mentioned by commercial name, the dosage use indicated by
their manufacturer label was considered to establish the risk.
Regarding the association of medicines, the evidence of
fetal risk was investigated to each individual component of
the formulation. The formulation was classified as medicine
with known fetal risk when at least one of the components of
the formulation was identified with evidence of risk.
Statistical analyses were performed using SPSS version
18.0. We first analyzed the association between medicine
use in general and the use of unknown fetal risk medicines.
We then repeated the analyses after excluding vitamins and
iron supplements. The variables of interest were: trimester
in which the medicine was used, age of the mother, skin
color, years of schooling, marital status, per capita income,
birth order, number of prenatal consultations, gestational
week of the first prenatal consultation, hospitalization during
pregnancy, and the presence of the following self reported
clinical conditions: hypertension, diabetes, depression, ane-
mia, threatened abortion, threatened premature birth, and
urinary tract infection. Chi-square tests were used for
comparing proportions. Logistic regression was used for
adjusted analysis, adjusting all the variables of interest. A
significance level of 5% was employed.
The study was approved by the School of Medicine Ethics
Committee of the Federal University of Pelotas.
3. Results
Out of a total of 4,189 interviewed pregnant women, 92.7%
reported the use of some medicine during pregnancy, total-
ing the use of 11,425 medicines. The number of medicines
used during gestation ranged from 1 to 10 medicines by preg-
nant women with an average of 2.9 (SD 1.6). Considering the
pregnancy trimesters, the average number of medicines used
was 1.3 (SD 0.6), 1.4 (SD 0.7), and 1.7 (SD 0.9) during the
first, second, and third trimesters, respectively. Among the
women who reported the use of medicines, 61.2% used one
or two medicines, 28.7%, three or four medicines and 10.3%,
five or more. If vitamins and iron are excluded from the
analyses, 1,829 pregnant women (43.7%) reported using at
least one medicine, adding up to the use of 7,860 medicines.
Out of all medicines used, 38.9% were identified as
unknown fetal risk. More than half of all mothers used at
least one product with unknown fetal risk (52.5%).
Table 1 summarizes the results for the trimester of the
first usage for each medicine as well as the period of their
use. The number of medicines with usage initiated in each
trimester was very homogeneous (around 30% for each
trimester) and the largest proportion of medicines was used
exclusively in the third trimester. Only 5.1% of the medicines
used in the first trimester were also used during the second
trimester and 14.6% of the medicines were used during the
three trimesters.
The most commonly used medicines with unknown fetal
risk are presented in Table 2, by the gestational trimester of
use. Multivitamins and the association between scopolamine
butyl bromide and dipirone accounted for more than 50% of
the medicines used in any time during pregnancy.
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Table 1: Medicines used by the mothers participating in the 2004 Birth Cohort by the gestational trimester and percentages of mothers who
used at least one medicine in the respective periods. Birth Cohort of Pelotas, RS 2004.
Trimester
Medicines (n = 11,425) Mothers (n = 3,883)
n % n %
Start of the use of medicinesa
1st 3,241 29.9 1,909 50.0
2nd 3,847 35.6 2,377 62.2
3rd 3,738 34.5 2,260 59.1
Total 10,826 100.0 3,821c e
Period of the use of medicinesb
1st 1,093 10.1 848 22.2
2nd 1,884 17.5 1,366 35.8
3rd 3,734 34.7 2,259 59.2
1st and 2nd 545 5.1 467 12.2
2nd and 3rd 1,939 18.0 1,504 39.4
1st, 2nd and 3rd 1,575 14.6 1,170 30.7
Total 10,770 100.0 3,814d e
a
599 missing; b655 missing; c62 missing; d69 missing; ethe percentages do not add up to 100% since each mother who used any medicine could have used
more than one medicine in the same period or in different periods.
Table 2: Most used medicines by the mothers participating in the 2004 Birth Cohort classified as unknown fetal risk, by the gestational
trimester of medicine use. Birth Cohort of Pelotas, RS 2004.
Trimester of usea
Medicines used at any time during
pregnancy
Total










1st, 2nd, and 3rd
(N = 526)
% % % % % % %
Multivitamins 31.2 17.4 20.0 26.6 35.9 46.8 44.8
Scopolamine Butylbromide +
dipyrone
27.7 37.6 31.7 32.0 23.7 19.6 21.7
Aluminium hydroxideb 7.4 4.5 4.6 3.9 5.3 8.9 6.5
Piperidolate + hesperidine + ascorbic
acid
6.5 12.0 6.4 5.1 16.8 6.1 7.2
Nystatin 5.2 7.4 11.5 7.7 0.8 1.3 0.7
Sodium bicarbonateb 3.3 2.9 1.1 0.8 0.8 2.7 4.8
Ferrous sulphate + ascorbic acid +
folic acid
3.0 2.5 1.6 0.8 4.6 4.1 8.7
Salbutamol 2.6 0.4 2.3 5.2 0.0 2.0 1.3
Isoxsuprine 2.2 1.2 2.5 3.5 1.5 2.1 0.7
Miconazole 1.9 1.7 4.4 2.8 0.0 1.1 0.0
Ascorbic acid 1.6 2.5 0.9 1.9 0.8 1.8 1.3
Diclofenac 1.4 2.9 1.8 1.6 3.8 0.4 0.4
Norfloxacin 1.2 0.8 3.0 1.8 0.0 0.1 0.2
Dimethicone 0.8 0.0 0.7 0.8 1.5 0.9 1.1
Terconazole 0.8 0.8 3.4 0.8 0.8 0.0 0.0
Promethazine 0.8 0.4 0.9 1.3 2.3 0.4 0.4
Betamethasone 0.6 0.0 0.5 1.4 0.0 0.3 0.2
Trimethoprim-sulfamethoxazole 0.6 1.7 1.1 0.5 0.0 0.4 0.0
Pipemidic acid 0.6 0.8 1.6 0.8 0.0 0.1 0.0
Fluoxetine 0.6 2.5 0.0 0.5 1.5 0.7 0.0
Others 8.9 17.1 17.3 20.2 18.1 7.7 12.5
a
There is no information about in which gestational trimester was the use of 177 medicines classified as unknown fetal risk.
bMedicine used individually or in association.
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Table 3 presents demographic, socioeconomic, and
health characteristics of the mothers during pregnancy. Data
on the total prevalence of use of medicines (92.7%) and
on the use of medicines with unknown fetal risk (52.5%)
according to such variables are presented. The following
variables remained associated to the use of medicines with
unknown fetal risk after adjusted analyzes: white skin color,
education and per capita income (in direct proportion to
use), six or more prenatal consultations, hospitalization,
and morbidity during the pregnancy (depression, anemia,
threat of abortion, threat of premature labor, and urinary
infection).
Table 4 presents the same analysis conducted in Table 3,
but excluding vitamin and iron supplements. The total
prevalence of use of medicines excluding vitamins and
iron was 43.7%. The prevalence of use of medicines with
unknown fetal risk was 25.6%. The following variables were
associated with the use of medicines with unknown fetal risk
in the adjusted analyses: per capita income, hospitalization,
threat of abortion, and threat of premature labor.
In Table 5 we analyzed only women who reported to
have diabetes or hypertension. Medicines used for treating
diabetes were insulin and metformin, and, for hypertension
the most frequent medicine used was methyldopa followed
by others with low frequencies classified as “unknown risk”.
The prevalence of use of antidiabetics was 13.8% and
the prevalence of use of antihypertensives medication was
25.8%. Among diabetic women, no antidiabetic medicine of
unknown fetal risk was reported to be used, whereas 38% of
the other medicines used were classified as of unknown fetal
risk. Among hypertensive women, 9.6% of the hypertension
medication used was classified as of unknown fetal risk,
whereas 41.3% of the other medicines used were classified
as such.
4. Discussion
In this study the frequency of exposure to medicines by
gestational trimesters, the identification of the medicines
with unknown information about fetal risk, and the main
factors associated to these medicines were examined. Some
features of this study are distinctive from other similar
studies in the literature: the inclusion of prescription and
over-the-counter medicines, since the majority of studies do
not consider medicines used for self-medication or those
prescribed during hospitalizations [16, 27], and collection
of data by interview with the mothers instead of using sec-
ondary data. Data presented here are directly generalizable
to the population of the city, because virtually all mothers
who gave birth in 2004 were included. Findings are also likely
valid for other areas of Brazil, which similarly to Pelotas have
huge socioeconomic disparities leading to inequities in access
to health care. Therefore, we believe data may be extrapolated
to other municipalities with similar characteristics thus
contributing to the improvement of knowledge regarding
factors associated to medicine use with unknown risk during
pregnancy in Brazil. Extrapolating our findings to other low
and middle income countries is likely misleading due to huge
heterogeneity in pharmaceutical policies.
The prevalence of the use of at least one medicine during
pregnancy was high; however, it is consistent with other
studies conducted in Brazil with prevalence over 90% [4, 9].
This usage is also quite high in other countries. However,
most studies investigated only the use of prescription
medicines [5, 16, 18, 28], potentially resulting in estimates
that are lower than the prevalence identified in this study.
Other fact to be considered is the type of question used in
our study. We opted to use an open-ended question followed
by selected indication-orientation (the question used in our
study is described in the methods section). de Jong-van
den Berg and colleagues [29] evaluated the influence of the
type of questions used in interviews about medicine use in
pregnancy, and concluded that the prevalence of medicine
use increases considerable when the question about medicine
use includes indication-orientation and drug-orientation to
the open-ended questioning. The authors also concluded
that these higher prevalence figures are more comparable
with pharmacy records.
It was observed that the prevalence of medicine use
by pregnant women exceeds the prevalence for women in
general [30–32]. In studies carried out in Brazil to evaluate
medicine utilization in the general population, women in
reproductive age (18 to 49 years old) presented prevalence of
medicine use from 42% [33] to 60.4% [30]. In a European
study it was found a slightly higher prevalence (68.8%),
considering women aged 25 to 44 years old. [32]. The use
of medicines indicated during the gestational period, such as
vitamins and iron derivatives, can explain these differences,
which is attenuated when these groups of medicines are
excluded from the analysis.
The present study reports the gestational trimester in
which the medicine use started, while available data in the
literature reports only whether the pregnant women were
exposed to medicines in different periods [3, 5, 8, 10, 34]. The
largest number of used medicines was reported as first used
during the second trimester (35.6%) and a slightly smaller
proportion (29.9%) was reported as first used during the
first trimester, which may indicate an issue of concern about
exposure to medicines in early pregnancy where the risks to
the fetus are known to be higher [35].
Only 14.6% of the medicines were used throughout the
entire gestational period, indicating that situations in which
the continued use of medicines is necessary are few. However,
this percentage does not necessarily indicate that medications
are unnecessary—the medication may be warranted, but
women may not continue use, due to nonadherence or
concerns about use after realizing that they are pregnant.
In addition, pregnant women are usually younger and
healthier that women in general, which leads to the use of
medicines for acute situations, such as infection, the control
of symptoms commonly associated with the pregnancy itself
(such as heartburn) or prophylactically indicated during the
pregnancy (such as folic acid).
Most studies classifying medicines in risk categories used
the FDA criteria [1, 4–7, 16, 18–21, 26, 28, 36]. Some studies
excluded vitamins and minerals [1, 18] from the analyses
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Table 3: Description of the sample and the health conditions of the mothers participating in the 2004 Birth Cohort (N), prevalence (P%)
and adjusted analyses of the use of medicines during pregnancy considering all medicines and the medicines with unknown fetal risk used.
Birth Cohort of Pelotas, RS 2004.
N Use of medicines (total) Use of medicines with unknown fetal risk
Characteristic Adjusted analyses Adjusted analyses
P% PR (IC 95%) P value P% PR (IC 95%) P value
Total of participants 4,189 92.7 — — 52.5 — —
Age 0,062 0.076
<20 796 90.8 1.00 43.6 1.00
20 to 29 2,085 93.1 1.58 (1.03–2.43) 53.2 1.09 (0.90–1.32)
30 to 39 1,170 92.9 2.01 (1.19–3.38) 56.9 1.31 (1.05–1.64)
40 or more 136 94.1 2.35 (0.83–6.62) 55.1 1.18 (0.76–1.84)
Skin color 0,08 <0.001
White 2,555 93.8 1.31 (0.97–1.78) 57.7 1.36 (1.17–1.58)
Non-white 1,586 90.9 1.00 44.1 1.00
Education in years 0.026 <0.001
0 to 4 647 87.3 1.00 32.8 1.00
5 to 8 1,711 91.6 1.50 (1.02–2.23) 47.0 1.70 (1.35–2.13)
9 to 11 1,396 95.1 1.90 (1.19–3.03) 62.7 2.57 (2.01–3.30)
12 or more 435 97.2 2.66 (1.22–5.79) 70.6 2.74 (1.95–3.85)
Marital status 0.064 0.92
With the baby’s father 3,502 93.1 1.44 (0.98–2.11) 53.5 0.99 (0.81–1.21)
Without 687 90.5 1.00 47.0 1.00
Income per capita 0.09 <0.001
1st quintile 830 88.4 1.00 38.2 1.00
2nd quintile 834 89.2 0.83 (0.55–1.25) 41.7 1.03 (0.82–1,30)
3rd quintile 886 94.2 1,48 (0.93–2.36) 52.7 1.29 (1.03–1.62)
4th quintile 849 94.7 1.11 (0.68–1.82) 61.1 1.79 (1.41–2.27)
5th quintile 790 96.8 1.55 (0.81–2.95) 69.2 1.94 (1.47–2.55)
Parity 0.025 0.52
primipara 1,658 94.8 2.45 (1.34–4.46) 55.9 1.12 (0.81–1.56)
1 or 2 1,086 93.0 1.65 (0.96–2.82) 54.8 1.06 (0.78–1.45)
3 or 4 1,026 91.6 1.36 (0.83–2.23) 48.6 0.95 (0.70–1.27)
5 or more 419 86.2 1.00 42.2 1.00
Prenatal consultation 0.004 0.001
<6 689 86.6 1.00 36.0 1.00
6 or more 3,250 94.9 1.65 (1.18–2.32) 56.8 1.39 (1.14–1.70)
Start of prenatal care 0.70 0.32
Before the 20th week 3,765 94.0 1.10 (0.68–1.80) 54.8 1.18 (0.85–1.64)
After the 20th week 283 84.8 1.00 31.4 1.00
Hospitalization
No 3,722 91.9 1.00 0.002 50.9 1.00 0.05
Yes 467 98.9 6.50 (1.99–21.21) 64.7 1.28 (1.00–1.62)
High Blood Pressure 0.012 0.87
No 3,189 92.3 1.00 52.6 1.00
Yes 992 94.0 1.60 (1.11–2.31) 52.3 0.90 (0.59–1.37)
Diabetes 0.76 0.63
No 4,062 92.6 1.00 52.4 1.00
Yes 124 96.0 0.86 (0.32–2.30) 56.4 0.90 (0.59–1.37)
Depression 0.034 <0.001
No 3,138 92.1 1.00 51.0 1.00
Yes 1049 94.3 1.49 (1.03–2.16) 56.9 1.38 (1.16–1.64)
Anemia <0.001 <0.001
No 1,402 83.0 1.00 42.7 1.00
Yes 2756 97.8 10.79 (7.68–15.16) 57.7 1.53 (1.31–1.78)
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Table 3: Continued.
N Use of medicines (total) Use of medicines with unknown fetal risk
Characteristic Adjusted analyses Adjusted analyses
P% PR (IC 95%) P value P% PR (IC 95%) P value
Threat of abortion 0.15 <0.001
No 3,736 92.2 1.00 50.0 1.00
Yes 449 96.4 1.55 (0.85–2.83) 73.0 2.40 (1.84–3.11)
Threat of premature labor <0.001 <0.001
Não 3,416 91.7 1.00 48.0 1.00
Sim 771 97.0 2.72 (1.57–4.73) 72.5 2.65 (2.15–3.27)
Urinary Infection <0.001 0.012
Não 2,623 89,8 1.00 52.5 1.00
Sim 1,552 97.7 5.53 (3.58–8.54) 52.5 0.82 (0.71–0.96)
∗
Chi square test; ∗∗1st quintile relates to the most deprived quintile ∗∗∗PR: prevalence ratio.
while others evaluated the use of the medicines in part of
the gestation period (up to the gestational age at the time
of the interview) [23, 36]. Only studies that evaluated the use
of medicines throughout the whole gestational period and
included vitamins and minerals were selected for the purpose
of comparisons with our data [4–7, 16, 18, 21, 28].
The frequency of the use of medicines with unknown
fetal risk (38.9%) is consistent with a study conducted with
parturients interviewed after childbirth in a hospital from
another Brazilian city (42.4%) [4], however, higher than the
reported frequency in a study conducted in a city in southern
Brazil (24.5%) [6] and in Ethiopia (15.2%) [7].
The prevalence of women exposed to the medicines with
unknown fetal risk (52.5%) was higher than that observed
in most studies (14.7 to 19%) [5, 7, 28] but lower than the
one reported in the study by Lacroix (85.0%) [16]. The study
by Lacroix presents the peculiarity of inclusion of products
that generally were not included in other studies, such as
homeopathic remedies [37], thus leading to its elevated per-
centages. Other studies do not mention having investigated
the primary literature about teratogenic risk, which may have
led to an underestimated classification of many medicines
in this group [5, 7, 18, 21, 28]. According to the FDA’s
recommendations, the use of these medicines should only
occur when the potential benefits justify the potential risks
to the fetus. As a consequence, the uncertainty about the
risks associated with this category can generate doubts and
anxiety in doctors and pregnant women. However, medical
information justifying the use of these medicines by each
pregnant woman is not available for analysis, which would
allow a better assessment of the impact from the use of these
medicines.
Formulations with multiple vitamins stood out in the
analyses of the medicines with unknown fetal risk during
pregnancy. The risk of some vitamins during gestation
is dose-dependent. The multivitamin’s components were
analyzed individually and classified according to their dosage
in the formulation. According to Briggs et al. [26], the
following vitamins, in concentrations higher than the ones
described as follows, present unknown fetal risk: vitamin B1
(1.5 mg), vitamin B2 (1.6 mg), vitamin B5 (10 mg), vitamin
B12 (2.2–2.6 µg), vitamin C (70 mg), vitamin E (10 mg), and
nicotinamide (17 mg). The following vitamins show positive
evidence of fetal risk in concentrations higher than 400 IU
and 8,000 IU/day, respectively, for Vitamin D (and D3) and
vitamin A.
The use of multivitamins during pregnancy is often
suggested as an intervention aimed at improving maternal
and fetal health. However, substantive evidence regarding the
effectiveness of multiple-micronutrient supplements during
pregnancy is not available. Its use during the prenatal period
is associated with controversial results in the literature which
points to positive results [38] and lack of effect [39] in
terms of the benefit of multivitamins in the outcome of
low birth weight. There is not sufficient evidence for other
relevant clinical outcomes. Therefore, the use of this type
of medicine, advocated in the obstetric practice, should be
assessed considering the different existing formulations in
the market and acknowledging that, depending on the dose
present in the formulation its use is only justified if the
potential benefits overcome the potential risks for the fetus.
The analysis of the variables potentially related to a
greater use of medicines with unknown fetal risk was also
performed for the use of all medicines during pregnancy.
White women with higher education and greater income
used more medicines with unknown fetal risk. In general,
higher education alone was associated with greater use of
medicines, which is in agreement with a study conducted in
France and others in several Brazilian cities [4, 23, 36, 40].
Primiparous status increases the proportion of the use of
medicines (excluding medicines with unknown fetal risk)
in this study and other studies in Brazil [23, 36]. Mothers
who had a greater number of prenatal consultations used
more medicines in general and specifically medicines with
unknown fetal risk. However, the use of medicines is not
associated to the initiation of prenatal care occurring either
before or after the 20th week of gestation. In the study by
Guerra et al., prenatal care in the 1st trimester was associated
with a higher use of medicines [36].
Generally speaking, the presence of morbidity was
associated to an increased risk of the use of medicines in
general and also medicines with unknown fetal risk. This
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Table 4: Description of the sample and the health conditions of the mothers participating in the 2004 Birth Cohort (N), prevalence (P%)
and adjusted analyses of the use of medicines during pregnancy considering all medicines and the medicines with unknown fetal risk used,
excluding vitamin and iron supplements. Birth Cohort of Pelotas, RS 2004.
Use of medicines (total) Use of medicines with unknow fetal risk
Characteristic N P Adjusted analyses P Adjusted analyses
% PR (IC 95%) P value % PR (IC 95%) P value
Total of participants 4,189 43.7 — — 25.6 — —
Age 0.275 0.883
<20 796 38.8 1.00 24.5 1.00
20 to 29 2,085 44.6 1.19 (0.98–1.44) 26.1 0.98 (0.78–1.23)
30 to 39 1,170 44.8 1.21 (0.98–1.50) 25.7 0.93 (0.70–1.23)
40 or more 136 47.8 1.25 (0.82–1.88) 23.5 0.85 (0.51–1.40)
Skin color 0.038 0.154
White 2,555 45.8 1.17 (1.01–1.35) 27.0 1.12 (0.96–1.32)
Non-white 1,586 40.2 1.00 23.1 1.00
Education in years 0.002 0.075
0 to 4 647 40.6 1.00 19.8 1.00
5 to 8 1,711 40.6 1.09 (0.88–1.35) 25.0 1.28 (1.02–1.61)
9 to 11 1,396 47.9 1.42 (1.12–1.79) 28.2 1.39 (1.08–1.78)
12 or more 435 46.9 1.56 (1.14–2.13) 28.5 1.36 (1.00–1.89)
Marital status 0.615 0.331
With the baby’s father 3,502 44.2 1.05 (0.86–1.29) 26.0 1.11 (0.90–1.39)
Without 687 41.0 1.00 23.3 1.00
Income per capita 0.009 0.020
1st quintile 830 39.0 1.00 20.5 1.00
2nd quintile 834 40.3 1.03 (0.83–1.28) 24.8 1.26 (1.00–1.59)
3rd quintile 886 45.8 1.37 (1.10–1.70) 24.8 1.21 (1.00–1.53)
4th quintile 849 46.5 1.37 (1.09–1.72) 28.5 1.45 (1.14–1.84)
5th quintile 790 46.6 1.30 (1.01–1.68) 29.5 1.48 (1.14–1.92)
Parity 0.991 0.830
primipara 1,658 43.5 0.99 (0.72–1.37) 26.5 0.94 (0.67–1.32)
1 or 2 1,086 44.5 1.01 (0.75–1.37) 25.9 0.91 (0.66–1.26)
3 or 4 1,026 44.4 0.98 (0.74–1.30) 24.5 0.88 (0.65–1.19)
5 or more 419 40.3 1.00 23.9 1.00
Prenatal consultation 0.747 0.277
<6 689 42.8 1.00 24.2 1.00
6 or more 3,250 43.9 0.96 (0.77–1.20) 26.2 0.88 (0.70–1.11)
Start of prenatal care 0.861 0.517
Before the 20th week 3,765 43.7 0.97 (0.71–1.33) 26.2 1.12 (0.80–1.58)
After the 20th week 283 40.6 1.00 20.8 1.00
Hospitalization <0.001 <0.001
No 3,722 42.1 1.00 24.3 1.00
Yes 467 56.3 1.51 (1.20–1.89) 35.5 1.48 (1.19–1.84)
High Blood Pressure <0.001 0.305
No 3,189 40.9 1.00 25.1 1.00
Yes 992 52.5 1.62 (1.38–1.90) 27.2 1.10 (0.92–1.31)
Diabetes 0.995 0.390
No 4,062 43.5 1.00 25.4 1.00
Yes 124 50.8 1.00 (0.67–1.50) 32.3 1.20 (0.79–1.81)
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Table 4: Continued.
Use of medicines (total) Use of medicines with unknow fetal risk
Characteristic N P Adjusted analyses P Adjusted analyses
% PR (IC 95%) P value % PR (IC 95%) P value
Depression <0.001 0.066
No 3,138 41.5 1.00 24.8 1.00
Yes 1049 50.1 1.45 (1.24–1.70) 28.1 1.18 (0.99–1.40)
Anemia <0.001 0.366
No 1,402 64.4 1.00 24.2 1.00
Yes 2756 32.9 0.23 (0.20–0.26) 26.4 1.08 (0.92–1.26)
Threat of abortion 0.003 <0.001
No 3,736 42.3 1.00 24.4 1.00
Yes 449 54.6 1.39 (1.11–1.73) 35.6 1.48 (1.19–1.83)
Threat of premature labor <0.001 <0.001
Não 3,416 41.0 1.00 23.5 1.00
Sim 771 55.3 1.46 (1.22–1.76) 34.9 1.50 (1.25–1.80)
Urinary Infection <0.001 0.434
Não 2,623 38.6 1.00 24.6 1.00
Sim 1,552 52.2 2.10 (1.81–2.42) 27.2 1.06 (0.91–1.24)
∗
Chi square test; ∗∗1st quintile relates to the most deprived quintile, ∗∗∗PR: prevalence ratio.
Table 5: Medicine use among hypertensive and diabetic women. Birth Cohort of Pelotas, RS 2004.
Women with diabetes (n = 124)∗ Women with hypertension (n = 992)∗∗
Medicines N % % with unknown risk Medicines N % % with unknown risk
Antidiabetics 15 13.8 — Antihypertensives 219 25.8 9.6
Other 94 86.2 38.0 Other 630 74.2 41.3
∗
Casos válidos: 109 mulheres com informação sobre o nome dos medicamentos.
∗∗Casos válidos: 849 mulheres com informação sobre o nome dos medicamentos.
was verified among mothers who were hospitalized during
the pregnancy and those who presented depression, anemia,
threat of premature birth and urinary tract infection. A
greater risk of the use of medicines with unknown fetal
risk was not observed specifically by the mothers suffering
from high blood pressure since, methyldopa was among one
of the most used antihypertensive medications by pregnant
women. Methyldopa has not been confirmed to present a
risk to the embryo or fetus. The increased use of medicines
among mothers with chronic diseases was also verified in
studies by Costa da Fonseca et al. and Guerra et al. [4, 36].
In order to have some information about use of
medicines to treat chronic diseases in pregnancy, we analyzed
pregnant women with diabetes and hypertension due to
the high burden of disease caused by these two illnesses
in Brazil. It was observed that all antidiabetics and most
antihypertensive products are of known risk, with only a
small percentage of antihypertensive medicines classified
as unknown fetal risk. This might be explained by more
rigorous prescription patterns for treating these two diseases
due to their high burden.
It was possible to identify that vitamins and iron
supplements play a key role at increasing the prevalence
of use of medicines with unknown fetal risk in pregnancy.
Another issue to be considered is that due to the low cost
of iron supplements, these products are widely used by
all socioeconomic groups, and therefore, exclusion of them
from the analyses maximizes the differences between low
and high income women. The association of number of
antenatal consultations and use of medicines was also no
longer significant when vitamin and iron supplements were
excluded from the analysis. The use of such products is more
common among low risk pregnant women and those with
higher number of antenatal care consultations, because the
prescription of antianemic products is highly prevalent in
Brazil despite some controversies in the literature [41].
We opted for the use of logistic regression in order to
maintain comparability with most of the previous published
studies in the subject. However, it should be noted that,
because the outcome “use of medicines” has high prevalence,
the odds ratios estimated by logistic regression are well above
their respective prevalence ratios.
The absence of a risk assessment in accordance with the
medicine doses used by mothers is a common problem in
most studies including this one. It is known that teratogenic
and fetotoxic effects are usually dependent on dosage and
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the length of usage time [37]. The fact that the investigation
about the use of medicines occurred in a single moment (at
the interview time), after childbirth, can lead to recall errors
as a function of the long period investigated (nine months).
In addition to this, the fact that the mothers did not have the
packaging of the used medicines at the time of the interview,
which often made it impossible for the identification of the
exact name of the medicine used and consequent inability
to assign it in the proper risk category due to its unknown
composition must also be considered in the overall analyses.
The risk evaluation by the FDA and other similar
classifications has been widely criticized, especially as they
lead to an incorrect impression that the risk increases from A
to X and that drugs from the same category present the same
potential risk. Further, the system does not address potential
developmental adverse events on the basis of expected
incidence, severity, or reversibility, nor whether there are
degrees of risk based on the dose, duration, frequency,
route, or gestational timing of exposure to a given product.
The FDA was led to propose, in 2008, a review to present
information about medicine use during pregnancy included
in the package insert of the medicines. This proposal about
the new regulation has been discussed, but until now the new
labeling requirements have not yet been initiated [26, 42, 43].
The FDA initiative to revise this classification contributes
to an important and necessary reflection about the safety of
medicines used during gestation, considering that the classi-
fication adopted for many years confounded the prescribers
in the moment to decide about the use or not of some
medicines. The majority of the medicines do not clearly state
the risk or safety associated with the use of the product. This
fact lead the category C to an uncertain category, where data
available do not state whether the medicines are safe or not.
5. Conclusion
Cohort studies aimed at the measurement of the conse-
quences of the use of medicines during pregnancy are
needed. For the advancement of knowledge in this subject,
the evaluation of dosages and duration of the use of each
medicine by the mothers during pregnancy should be cor-
related to the health outcomes of the mother and newborn
in different phases of development. Health professionals
should be frequently educated on relationships between
teratogenic agents and maternal and fetal health in order
to make appropriate recommendations regarding the use
of some medicines based on the best information available
and not solely based on classifications that are subject to
significant errors, especially for taking into account a short
term follow-up of the offspring. Little is known about long
term consequences for the offspring and for that reason these
classification systems have limitations.
In addition, regulatory changes obligating pharma-
ceutical companies to include more detailed information
about the risks associated with the use of medicines and
health professionals’ training are needed, particularly during
pregnancy, therefore empowering health professionals to
prescribe effective and safe medicines to patients.
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